(Q45357217)

13 December 2017

title

Virus like particle based strategy to elicit HIV-protective antibodies to the alpha-helic regions of gp41. (English)

1 reference

13 December 2017

1 reference

7

1 reference

13 December 2017

8

1 reference

13 December 2017

C Pastori

1

1 reference

13 December 2017

D Tudor

2

1 reference

13 December 2017

L Diomede

3

1 reference

13 December 2017

A S Drillet

4

1 reference

13 December 2017

A Jegerlehner

5

1 reference

13 December 2017

T A Röhn

6

1 reference

13 December 2017

language of work or name

English

0 references

publication date

2 June 2012

1 reference

13 December 2017

1 reference

13 December 2017

volume

431

1 reference

13 December 2017

issue

1-2

1 reference

13 December 2017

page(s)

1-11

1 reference

Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection

13 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.05.005

Neutralizing antiviral B cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.05.005

Immunization with HIV-1 gp41 Subunit Virosomes Induces Mucosal Antibodies Protecting Nonhuman Primates against Vaginal SHIV Challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.05.005

Direct antibody access to the HIV-1 membrane-proximal external region positively correlates with neutralization sensitivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.05.005

Mutilation of RNA phage Qbeta virus-like particles: from icosahedrons to rods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.05.005

Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the alpha-helix of gp41.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.05.005

Passively transmitted gp41 antibodies in babies born from HIV-1 subtype C-seropositive women: correlation between fine specificity and protection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.05.005

Role of repetitive antigen patterns for induction of antibodies against antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.05.005

Potent cross-group neutralization of primary human immunodeficiency virus isolates with monoclonal antibodies--implications for acquired immunodeficiency syndrome vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.05.005

Vaccines that facilitate antigen entry into dendritic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.05.005

Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.05.005

Maternal HIV-1 antibody and vertical transmission in subtype C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.05.005

Multiple tandem copies of conserved gp41 epitopes incorporated in gag virus-like particles elicit systemic and mucosal antibodies in an optimized heterologous vector delivery regimen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.05.005

The gp41 epitope, QARVLAVERY, is highly conserved and a potent inducer of IgA that neutralizes HIV-1 and inhibits viral transcytosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.05.005

TLR9 signaling in B cells determines class switch recombination to IgG2a

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.05.005

The coming of age of virus-like particle vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.05.005

Mucosal IgA in exposed, uninfected subjects: evidence for a role in protection against HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.05.005

Identification of amino acid substitutions associated with neutralization phenotype in the human immunodeficiency virus type-1 subtype C gp120.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.05.005

Nucleotide sequence of a ssRNA phage from Acinetobacter: kinship to coliphages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.05.005

Visualization by cryo-electron microscopy of genomic RNA that binds to the protein capsid inside bacteriophage MS2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.05.005

Native display of complete foreign protein domains on the surface of hepatitis B virus capsids.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.05.005

Maternal antibody response at delivery and perinatal transmission of human immunodeficiency virus type 1 in African women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.05.005

Rational design of a stable, freeze-dried virus-like particle-based vaccine formulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.05.005

The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.05.005

Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.05.005

Specificity of the autologous neutralizing antibody response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.05.005

Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.05.005

Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.05.005

A virus-like particle-based anti-nerve growth factor vaccine reduces inflammatory hyperalgesia: potential long-term therapy for chronic pain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.05.005

Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.05.005

Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.05.005

Protection of neonatal macaques against experimental SHIV infection by human neutralizing monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.05.005

A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.05.005

Protection against osteoporosis by active immunization with TRANCE/RANKL displayed on virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.05.005

Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.05.005

Versatile virus-like particle carrier for epitope based vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.05.005

The broadly neutralizing HIV-1 IgG 2F5 elicits gp41-specific antibody-dependent cell cytotoxicity in a FcγRI-dependent manner.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.05.005

HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.05.005

Cryo electron microscopy reconstructions of the Leviviridae unveil the densest icosahedral RNA packing possible.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.05.005

Prime boost vaccination approaches with different conjugates of a new HIV-1 gp41 epitope encompassing the membrane proximal external region induce neutralizing antibodies in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.05.005

Distribution and three-dimensional structure of AIDS virus envelope spikes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.05.005

Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.05.005

10.1016/J.VIROL.2012.05.005

7 January 2021

Identifiers

DOI

1 reference

13 December 2017

1 reference